Generic Aliqopa Availability

Last updated on Jun 11, 2025.

Aliqopa is a brand name of copanlisib, approved by the FDA in the following formulation(s):

ALIQOPA (copanlisib dihydrochloride - powder;intravenous)

• Manufacturer: BAYER HEALTHCARE
  Approval date: September 14, 2017
  Strength(s): 60MG/VIAL (discontinued) ^[RLD]

All of the above formulations have been discontinued.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aliqopa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
  Patent 10,383,876
  Issued: August 20, 2019
  Inventor(s): Peters Jan-Georg & Militzer Hans-Christian & Müller Hartwig
  Assignee(s): BAYER INTELLECTUAL PROPERTY GMBH
  

  The present invention relates:—to 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride salt of formula (II): or a tautomer, solvate or hydrate thereof;—to methods of preparing said dihydrochloride salt;—to said dihydrochloride salt for the treatment and/or prophylaxis of a disease;—to the use of said dihydrochloride salt for the preparation of a medicament for the treatment and/or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, more particularly for the treatment or prophylaxis of a cancer, particularly lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer, hepatocyte carcinoma, pancreatic cancer, hepatocyte carcinoma or breast cancer;—to a pharmaceutical composition comprising said dihydrochloride salt; and—to a pharmaceutical combination comprising said dihydrochloride salt in combination with one or more further pharmaceutical agents.

  Patent expiration dates:

  • March 29, 2032
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts
  Patent 9,636,344
  Issued: May 2, 2017
  Inventor(s): Peters Jan-Georg & Militzer Hans-Christian & Müller Hartwig
  Assignee(s): Bayer Intellectual Property GmbH
  

  The present invention relates

  Patent expiration dates:

  • March 29, 2032
    
    ✓ 
    Patent use: TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
• Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
  Patent RE46856
  Issued: May 22, 2018
  Inventor(s): Hentemann Martin & Wood Jill & Scott William & Michels Martin & Campbell Ann-Marie & Bullion Ann-Marie & Rowley Bruce R. & Redman Aniko
  Assignee(s): Bayer Intellectual Property GMBH
  

  This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyperproliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.

  Patent expiration dates:

  • October 22, 2029
    
    ✓ 
    Patent use: TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
    ✓ 
    Drug substance
    ✓ 
    Drug product

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer